Lilly looks to take the top spot in Indian diabetes market

Published: 31-May-2013

Global awareness project and marketing distribution partnership with Indian pharma companies on the stocks


Eli Lilly has lined up a slew of initiatives to position itself as the top player in the antidiabetes space in India. Along with two new products to be rolled out this year, a US$30m global awareness project and marketing distribution partnership with Indian pharma companies is also on the stocks.

Late last year, the Indian arm of the company announced a 5-year $30m commitment to fight the rising burden of non-communicable diseases (NCD) in developing nations. Called the Lilly NCD Partnership, it will focus on creating awareness about diabetes in India and three other countries.

See more

You may also like

Manufacturing

Eli Lilly to build a new $3bn facility to boost oral medicine manufacturing capacity in Europe

Read more
The Netherlands site will bring 500 manufacturing and 1500 construction jobs while further strengthening Lilly's global supply chain

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Ardena strengthens leadership team with new quality and information officers Appointments reinforce focus on quality, compliance, and digital integration across global operations
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Embracing sustainable change through labelling choice Paavo Sillanpää, Senior Manager, Ecosystem Pharma and Healthcare, EMEIA, UPM Adhesive Materials, discusses the latest trends in pharmaceutical packaging and labelling and how producers can embrace future-focused solutions and sustainable options without compromising performance
  5. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company

You may also like

Manufacturing

Eli Lilly to build a new $3bn facility to boost oral medicine manufacturing capacity in Europe

The Netherlands site will bring 500 manufacturing and 1500 construction jobs while further strengthening Lilly's global supply chain
Manufacturing

Lilly partners with NVIDIA to build pharma’s most powerful AI supercomputer for faster drug discovery

Eli Lilly has joined forces with NVIDIA to create the world’s most powerful pharmaceutical supercomputer, designed to accelerate AI-driven medicine discovery and manufacturing — all while running entirely on renewable energy
Pharma 5.0

Pistoia Alliance launches Phase 3 of CMC Process Ontology to bridge life sciences data gap and accelerate AI adoption

Backed by major pharma companies, the initiative aims to standardise experimental and process data across R&D and manufacturing, enabling automation and AI-ready data throughout the life sciences industry
Analysis

Merck and others pull back from UK: what it means for pharma manufacturing

With pharma giant Merck pulling its own version of Brexit, what can the UK do to retain its drug manufacturing capabilities?
Research & Development

Prellis biologics partners with Eli Lilly to advance next-generation human antibody therapeutics

Prellis will combine its EXIS organoid and AntiGen AI platforms with Lilly’s research and development expertise, aiming to accelerate the discovery of fully human antibodies for multiple disease targets
Research & Development

Lilly’s oral GLP-1 orforglipron outperforms semaglutide in Phase III head-to-head trial

The results highlight orforglipron’s potential as a once-daily oral therapy to help more patients achieve near-normal glucose levels and meaningful weight reduction
Research & Development

Eli Lilly licenses Alchemab Therapeutics' ALS therapeutic antibody, ATLX-1282, for $415m

The IND-ready therapeutic antibody was discovered through Alchemab's machine learning and AI-powered platform, and has shown promise in treating ALS and FTD
Subscribe now